Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- RH + 9.8%, LULU +10.3% (also CEO to step down, also approves $1 bln increase to stock repurchase program) MITK +16.1%, NX +22%, JOUT +2.3%
Other news:
-
FOA +8.4% ($2.5 bln partnership with OWL funds to expand FOA's home equity lending)
-
WEST +6.2% (CEO bought 100,000 shares worth ~$414K)
-
FTI +5.5% (awarded significant contract from Chevron)
- ANIX +5.4% (announces positive phase 1 data for investigational breast cancer vaccine; primary endpoints were met and immune response observed in 74% of participants)
- BCRX +4.9% (announces FDA approval of ORLADEYO oral pellets, first and only oral prophylactic treatment for patients with HAE aged 2 to <12 years)
-
RLAY +4.7% (Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025)
-
SCVL +3.1% (announces new $50 million share repurchase program)
-
FLY +2.5% (names new COO),
-
CNP +2.4% (declares regular common stock dividend of $0.23/share from prior dividend of $0.22/share )
-
IBRX +2.3% ( receives EMA conditional marketing authorization recommendation for ANKTIVA with BCG for non-muscle invasive bladder cancer carcinoma in situ—a first in Europe)
-
CRNX +2% (first patient dosed in trial of atumelnant)
-
PLPC +2% (increases dividend)
-
AGRO +1.8% (priced its previously announced underwritten offering; Adecoagro will sell 41,379,311 common shares at a price per share to the public of $7.25, resulting in gross proceeds of approximately $300.0 million )
-
INVA +1.6% (announces publication in the lancet of positive Zoliflodacin Phase 3 data for the treatment of uncomplicated urogenital gonorrhea)
-
HST +1.2% (increases dividend and declares $0.15/sh special div),
-
YUMC +1.2% (expands share repurchase authorization by $1 billion )
- KNSL +1.1% (authorizes new $250 mln share repurchase program)